878799-20-3

Basic information

• Product Name: 1-BOC-AMINO-BUTYL-3-AMINE
• Synonyms: 1-BOC-AMINO-BUTYL-3-AMINE;Carbamic acid, N-(3-aminobutyl)-, 1,1-dimethylethyl ester;tert-Butyl (3-aMinobutyl)carbaMate;1-N-Boc-butane-1,3-diamine
• CAS NO: 878799-20-3
• Molecular Formula: C₉H₂₀N₂O₂
• Molecular Weight: 188.27
• Mol File: 878799-20-3.mol

Chemical Properties

• Boiling Point: 282.6°C at 760 mmHg
• Flash Point: 124.7°C
• Appearance: /
• Density: 0.972g/cm³
• Vapor Pressure: 0.00333mmHg at 25°C
• Refractive Index: 1.455
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 12.77±0.46(Predicted)
• CAS DataBase Reference: 1-BOC-AMINO-BUTYL-3-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BOC-AMINO-BUTYL-3-AMINE(878799-20-3)
• EPA Substance Registry System: 1-BOC-AMINO-BUTYL-3-AMINE(878799-20-3)

Safety Data

• Hazardous Substances Data: 878799-20-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-BOC-AMINO-BUTYL-3-AMINE is used as a key intermediate in the synthesis of various pharmaceuticals for the treatment of different diseases. Its unique structure and properties allow it to participate in a wide array of chemical reactions, contributing to the development of novel drug candidates.
Used in Drug Discovery:
1-BOC-AMINO-BUTYL-3-AMINE is utilized as a building block in drug discovery, where its reactivity and the presence of the BOC protective group enable the creation of diverse chemical entities with potential therapeutic applications.
Used in Chemical Reactions:
In the realm of chemical reactions, 1-BOC-AMINO-BUTYL-3-AMINE is employed as a reactant to form new compounds with specific properties, further expanding its utility in the pharmaceutical and chemical industries.
Used in Research and Development:
1-BOC-AMINO-BUTYL-3-AMINE is also used in research and development settings, where scientists explore its potential applications and interactions with other compounds to uncover new avenues for drug development and therapeutic interventions.

InChI:InChI=1/C9H20N2O2/c1-7(10)5-6-11-8(12)13-9(2,3)4/h7H,5-6,10H2,1-4H3,(H,11,12)

Upstream product

• 6627-89-0 tert-butyl phenyl carbonate 
• 590-88-5 1-methyltrimethylenediamine 
• 878799-19-0 1,1-dimethylethyl phenylmethyl 1,3-butanediylbiscarbamate 

Downstream Products

• 878799-21-4 1,1-dimethylethyl (3-{[(2-chloro-4-fluorophenyl)sulfonyl]amino}butyl)carbamate 

Relevant articles and documents

Reinvestigating Old Pharmacophores: Are 4-Aminoquinolines and Tetraoxanes Potential Two-Stage Antimalarials?

The syntheses and antiplasmodial activities of various substituted aminoquinolines coupled to an adamantane carrier are described. The compounds exhibited pronounced in vitro and in vivo activity against Plasmodium berghei in the Thompson test. Tethering a fluorine atom to the aminoquinoline C(3) position afforded fluoroaminoquinolines that act as intrahepatocytic parasite inhibitors, with compound 25 having an IC50 = 0.31 μM and reducing the liver load in mice by up to 92% at 80 mg/kg dose. Screening our peroxides as inhibitors of liver stage infection revealed that the tetraoxane pharmacophore itself is also an excellent liver stage P. berghei inhibitor (78: IC50 = 0.33 μM). Up to 91% reduction of the parasite liver load in mice was achieved at 100 mg/kg. Examination of tetraoxane 78 against the transgenic 3D7 strain expressing luciferase under a gametocyte-specific promoter revealed its activity against stage IV-V Plasmodium falciparum gametocytes (IC50 = 1.16 ± 0.37 μM). To the best of our knowledge, compounds 25 and 78 are the first examples of either an 4-aminoquinoline or a tetraoxane liver stage inhibitors.

SUBSTITUTED ISOQUINOLINE DERIVATIVE

The present invention provides an isoquinoline-6-sulfonamide derivative that is useful as a novel pharmaceutical agent. The present invention provides an isoquinoline-6-sulfonamide derivative represented by Formula (1), a salt thereof, or a solvate of the

ACYCLIC 1,3-DIAMINES AND USES THEREFOR

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted -acyclic diamines according to Formula (I): or a pharmaceutically acceptable salt thereof, or a solvate thereof, or a combination thereof, wherein: the R groups are as defined herein. The present invention also relates to a pharmaceutical composition and a method of treatment using the compound of Formula (I).